{Reference Type}: Journal Article
{Title}: Thrombocytopenia 4 (THC4): Six novel families with mutations of the cytochrome c gene.
{Author}: Marzollo A;Zampieri S;Barozzi S;Yousaf MA;Quartararo J;De Rocco D;Faleschini M;Marconi C;Ceccatelli Berti C;Bozzi V;Russo G;Giordano P;Goffrini P;Bresolin S;Pastore A;Savoia A;Pecci A;
{Journal}: Br J Haematol
{Volume}: 205
{Issue}: 1
{Year}: 2024 Jul 30
{Factor}: 8.615
{DOI}: 10.1111/bjh.19567
{Abstract}: Thrombocytopenia 4 (THC4) is an autosomal-dominant thrombocytopenia caused by mutations in CYCS, the gene encoding cytochrome c (CYCS), a small haeme protein essential for electron transport in mitochondria and cell apoptosis. THC4 is considered an extremely rare condition since only a few patients have been reported so far. These subjects presented mild thrombocytopenia and no or mild bleeding tendency. In this study, we describe six Italian families with five different heterozygous missense CYCS variants: p.Gly42Ser and p.Tyr49His previously associated with THC4, and three novel variants (p.Ala52Thr, p.Arg92Gly, and p.Leu99Val), which have been classified as pathogenic by bioinformatics and segregation analyses. Moreover, we supported functional effects of p.Ala52Thr and p.Arg92Gly on oxidative growth and respiratory activity in a yeast model. The clinical characterization of the 22 affected individuals, the largest series of THC4 patients ever reported, showed that this disorder is characterized by mild-to-moderate thrombocytopenia, normal platelet size, and function, low risk of bleeding, and no additional clinical phenotypes associated with reduced platelet count. Finally, we describe a significant correlation between the region of CYCS affected by mutations and the extent of thrombocytopenia, which could reflect different degrees of impairment of CYCS functions caused by different pathogenetic variants.